Life Cycle Investment Partners Ltd Takes $1.42 Million Position in Gilead Sciences, Inc. $GILD

Key Points

• Life Cycle Investment Partners Ltd disclosed a new position in Gilead Sciences during the fourth quarter, buying 11,553 shares worth about $1.42 million.
• Institutional ownership remains very high, with several other hedge funds and asset managers also increasing their stakes in Gilead recently.
• Gilead’s latest results topped expectations, and analysts remain broadly constructive: the company beat quarterly EPS and revenue estimates, while the consensus rating is still Moderate Buy with an average price target of $156.93.

Life Cycle Investment Partners Ltd purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,553 shares of the biopharmaceutical company's stock, valued at approximately $1,418,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock valued at $8,713,000 after acquiring an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 249.1% during the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock worth $1,115,000 after purchasing an additional 7,168 shares during the period. Sector Gamma AS lifted its holdings in shares of Gilead Sciences by 15.9% during the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company's stock worth $16,344,000 after purchasing an additional 20,239 shares during the period. NewEdge Wealth LLC grew its stake in shares of Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company's stock worth $75,962,000 after purchasing an additional 17,284 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its stake in shares of Gilead Sciences by 589.4% in the third quarter. First Citizens Bank & Trust Co. now owns 72,471 shares of the biopharmaceutical company's stock worth $8,044,000 after purchasing an additional 61,959 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Truist Financial reissued a "buy" rating and issued a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Wall Street Zen downgraded Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 9th. Maxim Group raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Finally, BMO Capital Markets lifted their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, January 26th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $156.93.

Gilead Sciences Price Performance

Shares of GILD opened at $134.36 on Monday. The company has a market capitalization of $166.82 billion, a PE ratio of 18.31 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The stock's 50-day moving average price is $136.27 and its two-hundred day moving average price is $133.73. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm's revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences's payout ratio is currently 44.69%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for chronic hepatitis delta virus (HDV), making it the first and only approved treatment in the U.S. for this rare and serious liver disease. That opens a new commercial opportunity in a high-unmet-need market. Article Title
• Positive Sentiment: Gilead also received a CHMP positive opinion in Europe for Trodelvy in first-line metastatic triple-negative breast cancer, supporting broader international adoption of one of its key oncology products. Article Title
• Positive Sentiment: Gilead completed its Tubulis acquisition, adding next-generation antibody-drug conjugate assets and strengthening its oncology pipeline. Article Title
• Positive Sentiment: Analysts at Zacks Research raised near-term EPS estimates for some periods and maintained strong longer-term profit expectations, which can support investor confidence in Gilead’s earnings outlook. Article Title
• Neutral Sentiment: Gilead announced a renewed collaboration with the World Health Organization to help eliminate visceral leishmaniasis, a public-health initiative that is strategically positive but likely not an immediate stock driver. Article Title
• Negative Sentiment: Some analyst updates trimmed certain 2026–2028 earnings estimates, which may temper enthusiasm around the stock’s longer-term growth rate, even as recent product news remains favorable. Article Title

Insider Activity

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares of the company's stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock valued at $8,523,570 in the last ninety days. 0.30% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.